Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

NCT07507188 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Amivantamab SC + Lazertinib PO
DRUG: Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)

Sponsor

Yonsei University